<DOC>
	<DOCNO>NCT02134613</DOCNO>
	<brief_summary>Rheumatoid psoriatic arthritis patient benefit anti-TNF-α therapy , effective reduce joint skin manifestation 60-70 % patient inflammatory articular joint skin disease . Thus , identify presence amount TNF-α joint skin patient may help guide course treatment efficiently . The investigator research group develop novel approach label anti-TNF-α technetium-99m . Here investigator compare result obtain scintigraphy MRI rheumatoid psoriatic arthritis . The 99mTc-anti-TNF-α scintigraphy might recognize molecule involve inflammatory process provide crucial information help physicians take decision drug use base biological evidence cost-effective appropriate treatment choice . It allow direct identification monoclonal antibody anti-TNF-α articular joint skin also ensure drug reach therapeutic target . It also allow correlation presence drug clinical response .</brief_summary>
	<brief_title>99mTc-anti-TNF-alpha Scintigraphy Evaluation Inflammatory Processes Activity</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Psoriatic</mesh_term>
	<criteria>Rheumatoid Arthritis ( RA ) patient must 1 joint edema . Inflammatory lumbalgia ankylose spondylitis Psoriatic arthritis active disease skin lesion Patients return scintigraphy Pregnancy , Lactation , active infection , severe concomitant disease medication allergy history</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>99mTc-anti-TNF</keyword>
	<keyword>Inflammation</keyword>
	<keyword>Psoriatic arthritis</keyword>
	<keyword>Rheumatoid arthritis</keyword>
</DOC>